Ondansetron Sandoz Ltd

Ondansetron, the active ingredient in Ondansetron Sandoz Ltd, is a 5-HT3 receptor antagonist presented as an intravenous formulation for intravenous use. It prevents nausea and vomiting associated with chemotherapy, postoperative recovery, and radiotherapy in patients.

GNH USA supplies Ondansetron Sandoz Ltd as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Ondansetron acts on the serotonin 5‑HT3 pathway to control emesis in several clinical settings.

Chemotherapy-induced nausea and vomiting: reduces the incidence and severity of nausea and vomiting in patients receiving cytotoxic chemotherapy. Postoperative nausea and vomiting: prevents nausea and vomiting after surgical procedures. Radiotherapy-induced nausea and vomiting: mitigates nausea and vomiting associated with radiation therapy.

Common Side Effects: - Headache - Constipation - Dizziness - Fatigue - Diarrhea - Abdominal discomfort

Serious or Rare Side Effects: - QT interval prolongation leading to arrhythmia - Severe allergic reactions (anaphylaxis, angioedema) - Serotonin syndrome when combined with serotonergic agents - Hypotension - Cardiac arrhythmias such as torsades de pointes

Ondansetron should be used with attention to patient‑specific risk factors and proper handling. - Assess cardiac risk: evaluate baseline QT interval before initiating therapy. - Monitor electrolytes: correct hypokalemia or hypomagnesemia to reduce arrhythmia risk. - Use cautiously in hepatic impairment: dose adjustment may be required. - Avoid concomitant QT‑prolonging drugs when possible: additive cardiac risk. - Pregnancy and lactation: prescribe only if potential benefit outweighs potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ondansetron may interact with several medication classes.

Major Interactions (Avoid): - Other QT‑prolonging agents (e.g., quinidine, amiodarone): additive risk of cardiac arrhythmia. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase ondansetron plasma concentrations. - Strong CYP2D6 inhibitors (e.g., quinidine, paroxetine): may raise ondansetron levels.

Moderate Interactions (Monitor Closely): - Apomorphine: can cause profound hypotension. - Aprepitant: may increase risk of QT prolongation when combined. - Rifampin: may reduce ondansetron exposure, potentially diminishing efficacy.